Literature DB >> 33253595

Self-Monitoring of Blood Glucose Requirements with the Use of Intermittently Scanned Continuous Glucose Monitoring: A Follow-Up Analysis Using Real-Life Data.

Monika Reddy1,2, Nick Oliver1,2.   

Abstract

Hypoglycemia-prone individuals with type 1 diabetes (T1D) who use intermittently scanned continuous glucose monitoring (isCGM) systems spend about 5 h/day in states where self-monitoring of blood glucose (SMBG) is indicated. Here we present estimates of the need for SMBG testing by retrospectively analyzing isCGM data from a cohort of real-world isCGM users. Data from 67 individuals were included in the analysis. Mean (SD) 3.18 (1.63) h/day was spent in an SMBG-indicated state and the number of transitions to an SMBG-indicated state was 3.86 (1.46)/day. Frequency of clinically important hypoglycemia [<3.0 mmol/L (<54 mmol/dL)] was median (IQR) 1.5 (0.6-3.4) episodes/week, of which only 50% were associated with a scan during the episode, and the average duration was 75.2 (63.9-91.8) min/episode. The need for continued SMBG testing remains important for all isCGM users and may affect the overall cost-effectiveness of isCGM. Impaired awareness of hypoglycemia and incidence of asymptomatic hypoglycemia may be underreported among real-life isCGM users in clinical practice.

Entities:  

Keywords:  Flash glucose monitoring; Hypoglycemia; Intermittently scanned continuous glucose monitoring (isCGM); Type 1 diabetes

Mesh:

Substances:

Year:  2020        PMID: 33253595     DOI: 10.1089/dia.2020.0477

Source DB:  PubMed          Journal:  Diabetes Technol Ther        ISSN: 1520-9156            Impact factor:   6.118


  2 in total

1.  The Importance of Patient and Family Engagement, the Needs for Self-Monitoring of Blood Glucose (SMBG) - Our Perspectives Learned Through a Story of SMBG Assistive Devices Made by a Husband of the Patient with Diabetes.

Authors:  Moritsugu Kimura; Masao Toyoda; Nobumichi Saito; Makiko Takahashi; Konomi Isozumi; Eri Kato; Daiji Kawanami; Masafumi Fukagawa
Journal:  Diabetes Metab Syndr Obes       Date:  2022-05-25       Impact factor: 3.249

2.  Long-term cost-effectiveness of Dexcom G6 real-time continuous glucose monitoring system in people with type 1 diabetes in Australia.

Authors:  J J Isitt; S Roze; D Tilden; N Arora; A J Palmer; T Jones; D Rentoul; P Lynch
Journal:  Diabet Med       Date:  2022-03-25       Impact factor: 4.213

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.